Naso-orbito-ethmoidal fracture main cause of traumatic NLDO

Article

Naso-orbito-ethmoidal fracture has been discovered as the main cause of traumatic nasolacrimal duct obstruction (NLDO), according to a paper in the European Journal of Ophthalmology.

Naso-orbito-ethmoidal fracture has been discovered as the main cause of traumatic nasolacrimal duct obstruction (NLDO), according to a paper in the European Journal of Ophthalmology.

Dr Bipasha Mukherjee et al., Department of Orbit, Oculoplasty, Reconstructive, and Aesthetic Surgery, Medical Research Foundation, Sankara Nethralaya, Chennai, India, reviewed 28 patients in the study. They retrospectively analysed data of the nature and pattern of injury, associated damage, clinical features, investigations, management, outcome and follow-up.

The most common cause of traumatic NLDO was high-velocity blunt injury encountered in road traffic accidents in 70% of patients, with the most common pattern of injury being naso-orbital-ethmoidal fractures in 64% of patients. Traumatic telecanthus was most commonly linked to periocular injury.

Of the the patients investigated, 75% were analysed with computed tomography-dacryocystography. External dacryocystorhinostomy was used to treat26 patients with or without silicon intubation and 2 patients underwent dacryocystorhinostomy. General and local anaesthesia was given to 68% and 32% of patients, respectively.

There was a successful outcome recorded in 96% of eyes operated with external dacryocystorhinostomy with or without silicone intubation. Telecanthus is an important presenting feature in the patients, with naso-orbito-ethmoidal fracture as the main cause of traumatic NLDO.

For the abstract please visit this page.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.